Co-Authors
This is a "connection" page, showing publications co-authored by Umberto Ricardi and Stefano Magrini.
Connection Strength
0.894
-
Applying radiation protection and safety in radiotherapy. Radiol Med. 2019 Aug; 124(8):777-782.
Score: 0.206
-
Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1077-1083.
Score: 0.155
-
COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiother Oncol. 2021 02; 155:120-122.
Score: 0.057
-
Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiol Med. 2021 Jan; 126(1):142-146.
Score: 0.055
-
COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiother Oncol. 2020 08; 149:89-93.
Score: 0.055
-
Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. J Contemp Brachytherapy. 2019 Feb; 11(1):48-53.
Score: 0.051
-
Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. Crit Rev Oncol Hematol. 2019 Feb; 134:87-103.
Score: 0.050
-
Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. Crit Rev Oncol Hematol. 2019 Feb; 134:104-119.
Score: 0.050
-
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health Qual Life Outcomes. 2018 Jun 13; 16(1):122.
Score: 0.048
-
Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. Eur Urol Focus. 2017 10; 3(4-5):321-324.
Score: 0.046
-
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiol Med. 2018 Jan; 123(1):48-62.
Score: 0.046
-
Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clin Exp Res. 2017 Apr; 29(2):165-172.
Score: 0.044
-
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol. 2012 Jun; 14(6):798-807.
Score: 0.032